RT Journal Article
SR Electronic
T1 Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people living with HIV with hyporesponse after primary vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.10.22278577
DO 10.1101/2022.08.10.22278577
A1 Marlou J. Jongkees
A1 Daryl Geers
A1 Kathryn S. Hensley
A1 Wesley Huisman
A1 Corine H. GeurtsvanKessel
A1 Susanne Bogers
A1 Lennert Gommers
A1 Grigorios Papageorgiou
A1 Simon P. Jochems
A1 Jan G. den Hollander
A1 Emile F. Schippers
A1 Heidi S.M. Ammerlaan
A1 Wouter F.W. Bierman
A1 Marc van der Valk
A1 Marvin A.H. Berrevoets
A1 Robert Soetekouw
A1 Nienke Langebeek
A1 Anke H.W. Bruns
A1 Eliane M.S. Leyten
A1 Kim C.E. Sigaloff
A1 Marit G.A. van Vonderen
A1 Corine E. Delsing
A1 Judith Branger
A1 Peter D. Katsikis
A1 Yvonne M. Mueller
A1 Rory D. de Vries
A1 Bart J.A. Rijnders
A1 Kees Brinkman
A1 Casper Rokx
A1 Anna H.E. Roukens
YR 2022
UL http://medrxiv.org/content/early/2022/08/10/2022.08.10.22278577.abstract
AB Background The COVIH study is a prospective SARS-CoV-2 vaccination study in people living with HIV (PLWH). Of the 1154 PLWH enrolled, 14% showed a reduced or absent antibody response after a primary vaccination regimen. As the response to an additional vaccination in PLWH with hyporesponse is unknown, we evaluated whether an additional vaccination boosts immune responses in these hyporesponders.Methods Consenting hyporesponders received an additional 100 µg of mRNA-1273. Hyporesponse was defined as ≤300 spike(S)-specific binding antibody units [BAU]/mL. The primary endpoint was the increase in antibodies 28 days after the additional vaccination. Secondary endpoints were the correlation between patient characteristics and antibody response, levels of neutralizing antibodies, S-specific T-cell and B-cell responses, and reactogenicity.Results Of the 75 PLWH enrolled, five were excluded as their antibody level had increased to >300 BAU/mL at baseline, two for a SARS-CoV-2 infection before the primary endpoint evaluation and two were lost to follow-up. Of the 66 remaining participants, 40 previously received ChAdOx1-S, 22 BNT162b2, and four Ad26.COV2.S. The median age was 63 [IQR:60-66], 86% were male, pre-vaccination and nadir CD4+ T-cell counts were 650/μL [IQR:423-941] and 230/μL [IQR:145-345] and 96% had HIV-RNA <50 copies/ml. The mean antibody level before the additional vaccination was 35 BAU/mL (SEM 5.4) and 45/66 (68%) were antibody negative. After the additional mRNA-1273 vaccination, antibodies were >300 BAU/mL in 64/66 (97%) with a mean increase of 4282 BAU/mL (95%CI:3241-5323). No patient characteristics correlated with the magnitude of the antibody response nor did the primary vaccination regimen. The additional vaccination significantly increased the proportion of participants with detectable ancestral S-specific B-cells (p=0.016) and CD4+ T-cells (p=0.037).Conclusion An additional mRNA-1273 vaccination induced a robust serological response in 97% of the PLWH with a hyporesponse after a primary vaccination regimen. This response was observed regardless of the primary vaccination regimen or patient characteristics.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe trial was registered in the Netherlands Trial Register (NL9214).Funding StatementThis study was funded by the Dutch Organization for Health Research and Development (ZonMw) [10430072010008] and the Health∼Holland [EMCLHS20017 to DG and RDdV] co-funded by the PPP Allowance made available by the Health∼Holland, Top Sector Life Sciences & Health, to stimulate public -private partnerships.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical research Ethics Committees United Nieuwegein (MEC-U, reference 20.125) of Our Lady Hospital (OLVG Hospital) gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.